Table 1. Prognostic factors of overall survival, as identified by univariate and multivariate analyses (n=40).
| Characteristic | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Value | P-value | Hazard ratio (95% CI) | P-value | |
| Time of diagnosis | 0.371 | |||
| Mean age (yr) | 66 (31–83) | - | ||
| ≤66 yr | 21 (52.5) | - | ||
| > 66 yr | 19 (47.5) | - | ||
| Sex | 0.059 | |||
| Male | 27 (67.5) | - | ||
| Female | 13 (32.5) | - | ||
| TNM | 0.011* | |||
| I | 10 (25.0) | - | ||
| II | 7 (17.5) | - | ||
| III | 6 (15.0) | - | ||
| IV | 17 (42.5) | - | ||
| CRP/alb ratio | <0.001* | 6.078 (1.971-18.743) | 0.002* | |
| ≤0.085 | 27 (67.5) | - | ||
| > 0.085 | 13 (32.5) | - | ||
| mGPS | <0.001* | |||
| 0 | 37 (92.5) | - | 0.044* | |
| 1 | 2 (5.0) | 4.949 (0.835-29.329) | 0.078 | |
| 2 | 1 (2.5) | 36.324 (2.33-566.372) | 0.01* | |
| NLR | 0.417 | |||
| ≤1.888 | 23 (57.5) | - | ||
| > 1.888 | 17 (42.5) | - | ||
| PLR | 0.025* | 4.827 (1.457-45.984) | 0.01* | |
| ≤124.8 | 20 (50.0) | - | ||
| > 124.8 | 20 (50.0) | - | ||
| PNI | 0.002* | |||
| ≤50.55 | 16 (40.0) | - | ||
| > 50.55 | 24 (60.0) | - | ||
| Size of primary tumor (cm) | 0.037* | |||
| ≤2.8 | 19 (47.5) | - | ||
| > 2.8 | 21 (52.5) | - | ||
| Lymph node metastasis | 0.03* | |||
| No | 30 (75.0) | - | ||
| Yes | 10 (25.0) | - | ||
| Distant metastasis | 0.079 | |||
| No | 37 (92.5) | - | ||
| Yes | 3 (7.5) | - | ||
(CRP/alb: C-reactive protein/albumin, mGPS: modified Glasgow Prognostic Score, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, PNI: prognostic nutritional index, CI: confidence interval)
*P<0.05.
Values are presented as mean (range) or number (%).